Research & Education

EGFR mutation not prognostic factor in non-small cell lung cancer

Smoking status seems to be most important prognostic factor

DENVER – Recent studies have demonstrated that molecular-targeted agents, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor

Greater representation of elderly patients in Phase III trials needed

Better representation can improve evidence-based treatment

DENVER – The median age of patients diagnosed with advanced non–small-cell lung cancer (NSCLC) has steadily increased over the recent years and is

Local therapy followed by treatment with EGFR TKI is well tolerated

Findings associated with prolonged progression-free and overall survival

DENVER – Local therapy is not commonly utilized in metastatic lung cancer.

Pathologists identify patterns of mutations to help inform design of future trials

Experts examine profiles from patients with early stage lung adenocarcinoma

DENVER – Molecular driven therapeutic targets have resulted in a paradigm shift in thetreatment of advanced lung adenocarcinoma.

Many doctors do not provide tobacco cessation assistance to lung cancer patients

Survey results from IASLC Tobacco Control and Smoking Cessation Committee

DENVER – Physicians who care for lung cancer patients recognize the importance of tobacco cessation, but often do not provide cessation assistance

Tumors with ALK rearrangements can harbor more mutations

More research needed to see if treatment should be altered for patients with coexisting mutations

DENVER – The identification of potentially targetable kinase mutations has been an exciting advancement in lung cancer treatment.

Pages